NFKB1 and B-cell chronic lymphocytic leukemia: Increasing the dose to 0.5 μM CW15337 almost completely sensitized CLL cells to the levels of 3T3 inactivated CLL cells, as now both the canonical and non-canonical NF-κB pathways were inhibited.